Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.

Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN.

PLoS One. 2015 Apr 2;10(3):e0116866. doi: 10.1371/journal.pone.0116866.

2.

Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.

Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN.

Clin Genitourin Cancer. 2016 Aug 17. pii: S1558-7673(16)30246-4. doi: 10.1016/j.clgc.2016.08.012. [Epub ahead of print]

PMID:
28089723
3.

Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.

Zubek VB, Konski A.

Mol Diagn Ther. 2009;13(1):31-47. doi: 10.2165/01250444-200913010-00006.

PMID:
19351214
4.

Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.

Michalopoulos SN, Kella N, Payne R, Yohannes P, Singh A, Hettinger C, Yousefi K, Hornberger J; PRO-ACT Study Group..

Curr Med Res Opin. 2014 Aug;30(8):1547-56. doi: 10.1185/03007995.2014.919908.

PMID:
24803160
5.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
6.

A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.

Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE.

JAMA. 1993 May 26;269(20):2650-8.

PMID:
8487449
7.

Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.

Parikh R, Sher DJ.

Cancer. 2012 Jan 1;118(1):258-67. doi: 10.1002/cncr.26272.

9.
10.

Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.

Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J.

BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789.

11.

Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.

Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM.

Urology. 2004 Jan;63(1):103-9.

PMID:
14751359
12.

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.

Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J.

Oncotarget. 2013 Apr;4(4):600-9.

13.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572.

PMID:
22966753
14.

Value of information on preference heterogeneity and individualized care.

Basu A, Meltzer D.

Med Decis Making. 2007 Mar-Apr;27(2):112-27.

PMID:
17409362
15.

Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.

Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ.

Cancer. 2007 Nov 15;110(10):2210-7.

16.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
17.

Pilot study of a utilities-based treatment decision intervention for prostate cancer patients.

Knight SJ, Nathan DP, Siston AK, Kattan MW, Elstein AS, Collela KM, Wolf MS, Slimack NS, Bennett CL, Golub RM.

Clin Prostate Cancer. 2002 Sep;1(2):105-14.

PMID:
15046701
18.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x.

19.

The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L.

CMAJ. 2000 Apr 4;162(7):977-83.

20.

A critique of the decision analysis for clinically localized prostate cancer.

Beck JR, Kattan MW, Miles BJ.

J Urol. 1994 Nov;152(5 Pt 2):1894-9.

PMID:
7933246
Items per page

Supplemental Content

Support Center